A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer

Jemal, 2015, Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations, JAMA, 314, 2054, 10.1001/jama.2015.14905 Dalela D, Sun M, Diaz M, et al. Contemporary trends in the incidence of metastatic prostate cancer among US men: results from nationwide analyses. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2017.04.012. Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900 Wallis, 2018, Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis, Eur Urol, 73, 834, 10.1016/j.eururo.2017.10.002 Saad, 2017, Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials, Prostate Cancer Prostat Dis, 20, 110, 10.1038/pcan.2016.62 Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 149, 10.1016/S1470-2045(12)70560-0 Sanders, 2016, Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine, JAMA, 316, 1093, 10.1001/jama.2016.12195 Sathianathen, 2018, Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer, Cochrane Database Syst Rev, 2018, CD160128 Leibowitz-Amit, 2015, Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer, J Geriatr Oncol, 6, 23, 10.1016/j.jgo.2014.09.183 Sathianathen NJ, Dahm P, Brown SJ, et al. Immediate abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. In press. Micromedex, 2017 Chastek, 2012, Health care costs for patients with cancer at the end of life, J Oncol Pract, 8, 75, 10.1200/JOP.2011.000469 Morgans, 2018, Quality of life during treatment with chemohormonal therapy: analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in prostate cancer, J Clin Oncol, 36, 1088, 10.1200/JCO.2017.75.3335 Chi, 2018, Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial, Lancet Oncol, 19, 194, 10.1016/S1470-2045(17)30911-7 Neumann, 2014, Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold, N Engl J Med, 371, 796, 10.1056/NEJMp1405158 Braithwaite, 2008, What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?, Med Care, 46, 349, 10.1097/MLR.0b013e31815c31a7 Woods, 2018, Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness, Eur Urol Oncol, 1, 449, 10.1016/j.euo.2018.06.004 Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005 Chow, 2013, Does enrollment in cancer trials improve survival?, J Am Coll Surg, 216, 774, 10.1016/j.jamcollsurg.2012.12.036 Gravis, 2018, Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies, Eur Urol, 73, 847, 10.1016/j.eururo.2018.02.001 Mohler, 2016, Prostate cancer, version 1.2016, J Natl Compr Cancer Netw, 14, 19, 10.6004/jnccn.2016.0004 Kruse, 2008, Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population, J Manage Care Pharm, 14, 844, 10.18553/jmcp.2008.14.9.844 Heijnsdijk, 2012, Quality-of-life effects of prostate-specific antigen screening, N Engl J Med, 367, 595, 10.1056/NEJMoa1201637